Half-life of Progesterone
The elimination half-life of progesterone varies significantly depending on the route of administration, ranging from approximately 5 to 16 hours for most clinically relevant formulations.
Oral Micronized Progesterone
The FDA-approved oral micronized progesterone formulation does not have a clearly defined elimination half-life in its pharmacokinetic profile 1. The FDA label describes absorption characteristics (Tmax of 1.5-2.3 hours) and distribution parameters but notably omits specific half-life data for the oral route 1.
Vaginal Administration
Vaginal progesterone demonstrates longer elimination kinetics compared to other routes:
- Terminal half-life: approximately 13-16 hours 2, 3
- A single 100 mg vaginal tablet achieves a mean terminal half-life of 16.39 ± 5.25 hours 2
- Another study using 50-100 mg vaginal tablets reported half-lives of 13.18 ± 1.3 hours and 13.7 ± 1.05 hours respectively 3
- Peak concentrations (Tmax) occur at approximately 6-7 hours after administration 2, 3
Percutaneous (Transdermal) Administration
Percutaneous progesterone exhibits the longest elimination half-life of approximately 30-40 hours, substantially longer than vaginal or intramuscular routes 4. This extended half-life reflects slow absorption from the skin depot and prolonged systemic clearance 4.
Intramuscular Administration (Animal Data)
In veterinary studies that may provide comparative context:
- Dogs receiving IM progesterone showed a mean elimination half-life of 12.1 hours (range 9.5-13.8 hours) 5
- Rats receiving IV progesterone demonstrated a distribution phase half-life of 0.13 hours and elimination phase half-life of 1.21 hours 6
Clinical Implications
Route-Dependent Pharmacokinetics
The substantial variation in half-life across routes has important clinical implications:
- Vaginal administration provides sustained progesterone levels with less frequent dosing requirements due to the longer half-life and "uterine first-pass effect" 2, 3
- Oral formulations require daily dosing given their pharmacokinetic profile, though specific half-life data is limited 1
- Transdermal formulations may allow for less frequent application due to the prolonged 30-40 hour half-life 4
Important Caveats
The FDA label for oral progesterone does not provide elimination half-life data, which is an unusual omission in pharmacokinetic characterization 1. This may reflect complex metabolism with multiple active metabolites (pregnanediols and pregnanolones) that undergo hepatic conjugation and enterohepatic recycling 1.
Progesterone undergoes extensive first-pass hepatic metabolism when administered orally, which significantly affects its bioavailability and pharmacokinetic profile 1. The drug is 96-99% protein-bound (primarily to albumin and transcortin), which influences its distribution and elimination 1.